UroGen Pharma Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that UroGen Pharma Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.13M | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | $283.0K | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | $364.0K | Feb 28, 2019 |
| FY2018 | Mar 31, 2018 | $481.0K | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $327.0K | Feb 28, 2019 |
| FY2018 | Sep 30, 2017 | $7.81M | Feb 28, 2019 |
| FY2018 | Mar 31, 2017 | $19.0K | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $17.53M | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.79M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $24.57M | Mar 10, 2025 |
| FY2024 | Sep 30, 2024 | $25.20M | Mar 10, 2025 |
| FY2024 | Jun 30, 2024 | $21.85M | Mar 10, 2025 |
| FY2024 | Mar 31, 2024 | $18.78M | Mar 10, 2025 |
| FY2024 | Dec 31, 2023 | $23.53M | Mar 10, 2025 |
| FY2024 | Sep 30, 2023 | $20.85M | Mar 10, 2025 |
| FY2024 | Jun 30, 2023 | $21.14M | Mar 10, 2025 |
| FY2024 | Mar 31, 2023 | $17.19M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $64.36M | Mar 14, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.34M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $22.09M | Mar 10, 2025 |
| FY2024 | Sep 30, 2024 | $22.75M | Mar 10, 2025 |
| FY2024 | Jun 30, 2024 | $19.62M | Mar 10, 2025 |
| FY2024 | Mar 31, 2024 | $17.05M | Mar 10, 2025 |
| FY2024 | Dec 31, 2023 | $21.24M | Mar 10, 2025 |
| FY2024 | Sep 30, 2023 | $18.49M | Mar 10, 2025 |
| FY2024 | Jun 30, 2023 | $18.70M | Mar 10, 2025 |
| FY2024 | Mar 31, 2023 | $14.93M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $56.70M | Mar 14, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($153.49M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | ($37.51M) | Mar 10, 2025 |
| FY2024 | Sep 30, 2024 | ($23.67M) | Mar 10, 2025 |
| FY2024 | Jun 30, 2024 | ($33.40M) | Mar 10, 2025 |
| FY2024 | Mar 31, 2024 | ($32.29M) | Mar 10, 2025 |
| FY2024 | Dec 31, 2023 | ($26.02M) | Mar 10, 2025 |
| FY2024 | Sep 30, 2023 | ($21.88M) | Mar 10, 2025 |
| FY2024 | Jun 30, 2023 | ($24.14M) | Mar 10, 2025 |
| FY2024 | Mar 31, 2023 | ($30.21M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($109.78M) | Mar 14, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($124.86M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($96.78M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($65.54M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($79.04M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($92.29M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($126.74M) | Mar 21, 2022 |
| FY2019 | Dec 31, 2019 | ($39.84M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($23.45M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($23.75M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($22.43M) | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.11M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $57.15M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $45.61M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $52.91M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $47.64M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $47.31M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $49.30M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $36.93M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $18.70M | Mar 2, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $155.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $121.15M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $93.27M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $82.84M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $87.54M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $90.22M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $60.20M | Mar 18, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($162.44M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($96.77M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($76.38M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($87.56M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($84.89M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($105.89M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($71.02M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($37.33M) | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | ($9.57M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $4.19M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $289.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $295.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $194.0K | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $254.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $752.0K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.22M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $325.0K | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $560.0K | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $271.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $695.0K | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $200.46M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $285.71M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $178.31M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $135.62M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $119.75M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $122.01M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $202.39M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $103.56M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $75.55M | Feb 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $305.93M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $294.51M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $243.52M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $224.98M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $111.33M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $25.65M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $22.09M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $13.47M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $7.04M | Feb 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($105.47M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($8.80M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($65.21M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($89.36M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $8.41M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $96.36M | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | $180.30M | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | $90.09M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | $68.52M | Mar 2, 2020 |
| FY2019 | Dec 31, 2016 | $16.31M | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($959.72M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($806.22M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($679.35M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($577.10M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($467.32M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($356.50M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($228.02M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($122.87M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($47.21M) | Feb 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.75M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $171.99M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $95.00M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $55.41M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $44.36M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $52.86M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $49.69M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $101.32M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $37.00M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.00M | Mar 2, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 10, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 10, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 10, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 10, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 10, 2025 |
| FY2024 | Jun 30, 2023 | (1) | Mar 10, 2025 |
| FY2024 | Mar 31, 2023 | (1) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 14, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.35M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 42.23M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 32.49M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 23.13M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 22.46M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 22.17M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 21.03M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 16.21M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 13.75M | Feb 28, 2019 |